Human leishmaniasis vaccines: Use cases, target population and potential global demand.
The development of vaccines against one or all forms of human leishmaniasis remains hampered by a paucity of investment, at least in part resulting from the lack of well-evidenced and agreed estimates of vaccine demand. Starting from the definition of 4 main use cases (prevention of visceral leishma...
Guardado en:
Autores principales: | Stefano Malvolti, Melissa Malhame, Carsten F Mantel, Epke A Le Rutte, Paul M Kaye |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0464839d58004701bab69217b060d1b0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.
por: Doumet Georges Helou, et al.
Publicado: (2021) -
Predictive models for the diagnostic of human visceral leishmaniasis in Brazil.
por: Tália S Machado de Assis, et al.
Publicado: (2012) -
A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?
por: Johan van Griensven, et al.
Publicado: (2014) -
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
por: Noushin Saljoughian, et al.
Publicado: (2013) -
Control of visceral leishmaniasis in latin america-a systematic review.
por: Gustavo A S Romero, et al.
Publicado: (2010)